Startup
Given the solid demand for tissue regeneration materials in the world, the startup has researched various avenues, all the way from gene regulation, protein engineering, and clinical research to product development and testing. With a focus on collagen matrix tissue regeneration materials and molecular image inspection, it has accomplished extraordinary results from experimental therapies of bone, alveolar, and cartilage defection and thus won recognition across the international academic community. Having developed well-rounded material extraction and manufacturing technologies and completed animal experiments, it is now ready to scale up its technological capability to benefit more people.
Guidance Rendered
- Guidance on applying for access to the MOEA’s A+ Program; implementation of the startup’s NT$24 million capital increase.
- Assistance in sorting out the specifications required for product development and pilot clinical trials under the MOEA’s A+ Program.